The index provider has partnered with biopharmaceutical royalties buyer Royalty Pharma to expand its thematic index suite of life science and biotech prop plays.
The initial indices will measure the performance of firms focused on delivering new and innovative therapeutic treatments related to virology and oncology. Royalty Pharma will provide input on certain medical conditions, clinical trials, and innovative therapies or technologies that may lead to breakthrough medical treatments. This will assist MSCI in the markup of a classification framework and index methodologies. There are three main drivers for structured product clients which include ESG
Continue reading with a subscription to the SRP market intelligence platform.
Request DemoAlready a subscriber? Login